Skip to main content
11 Feb | 2025

From girl to scientist: the journey of three referents on the Day of Women and Girls in Science

Once again, we join in the celebration of the International Day of Women and Girls in Science.

05 Feb | 2025

The winners of the second edition of the Pasqual Maragall’s grants programme visit the BBRC

Los investigadores han ofrecido presentaciones sobre sus principales líneas de investigación, financiadas con 800.000 € en la convocatoria de 2023

03 Feb | 2025

Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

This breakthrough has been made possible thanks to 360 middle-aged volunteers without cognitive impairment from the Alfa cohort, promoted by ”la Caixa” Foundation

15 Jan | 2025

Three years since the launch of the Fluid Biomarkers Facility

The laboratory has acquired new technologies and fostered internal and external collaborations

16 Dec | 2024

Dr. David Rotllant, new Interim Deputy Director of the Scientific Coordination Unit of the BBRC

Dr. David Rotllant assumes the responsibility of Interim Deputy Director of the Scientific Coordination Unit of the BBRC.

09 Dec | 2024

Barcelona consolidates its leadership in Alzheimer's research with the creation of the HUB Alzheimer Barcelona

This project, promoted by the Pasqual Maragall Foundation with the support of the Barcelona City Council, counts with the participation of the main public hospitals of the city and institutions specialized in Alzheimer's research.

29 Nov | 2024

"Science Week": Getting a good night's sleep is key to preventing Alzheimer's disease

We held an Instagram Live with Dr. Ana Fernández Arcos, neurologist and researcher at the Barcelonaβeta Brain Research Center, on the relationship between sleep and neurodegenerative diseases

27 Nov | 2024

We hold the annual meeting of the PROMINENT consortium

Representatives from 18 partner organizations have shared the progress of the project and decided on new actions for the future.

14 Nov | 2024

EMA recommends approval of lecanemab for the treatment of early-stage Alzheimer's disease

EMA approval of lecanemab after a first negative opinion in July of this year